Outcome of desensitization in human leukocyte antigen and ABO incompatible living donor kidney transplantation: Single center experience of first 200 incompatible transplants.
ABO incompatible
desensitization
donor specific anti-HLA antibodies
incompatible kidney transplant
preconditioning
therapeutic plasma exchange
Journal
Journal of clinical apheresis
ISSN: 1098-1101
Titre abrégé: J Clin Apher
Pays: United States
ID NLM: 8216305
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
revised:
20
08
2020
received:
08
07
2020
accepted:
12
11
2020
pubmed:
15
12
2020
medline:
15
12
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
Although desensitization is well established, concerns about graft outcome, patient survival and rejection still exist. The present study aims at comparing outcomes of renal transplant recipients across simultaneous ABO and human leukocyte antigen (HLA) incompatibility barriers to those with ABO or HLA incompatibility alone. This was a retrospective study conducted from October 2015 to December 2018. All patients with a clinical diagnosis of chronic kidney disease, who were prospective HLA incompatible (HLAi) and/or ABO incompatible (ABOi) renal transplant recipients were included. A total of 400 cases including 36 ABOi transplants, 154 HLAi transplants, 10 simultaneously ABO and HLA incompatible transplants, and 200 ABO (ABOc) and HLA (HLAc) compatible kidney transplants from living donors were included. There were significantly more number of blood transfusions, previous transplants and pregnancies in HLAi transplant recipients relative to the ABOi or the control group. Mean number of therapeutic plasma exchange procedures per patient and mean plasma volume processed per procedure were slightly higher in the ABOi + HLAi category. The incidence of graft dysfunction due to suspected antibody-mediated rejection during first year was highest in the ABOi + HLAi group, followed by ABOc + HLAi and ABOi + HLAc, lowest in the ABOc + HLAc category. Mean time to first episode of graft dysfunction was significantly shorter with incompatible transplants. There were no kidney transplant recipient deaths in the study. Patient outcome and graft outcomes observed with incompatible transplants were not worse than those observed with compatible transplants.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Although desensitization is well established, concerns about graft outcome, patient survival and rejection still exist. The present study aims at comparing outcomes of renal transplant recipients across simultaneous ABO and human leukocyte antigen (HLA) incompatibility barriers to those with ABO or HLA incompatibility alone.
MATERIALS AND METHODS
METHODS
This was a retrospective study conducted from October 2015 to December 2018. All patients with a clinical diagnosis of chronic kidney disease, who were prospective HLA incompatible (HLAi) and/or ABO incompatible (ABOi) renal transplant recipients were included. A total of 400 cases including 36 ABOi transplants, 154 HLAi transplants, 10 simultaneously ABO and HLA incompatible transplants, and 200 ABO (ABOc) and HLA (HLAc) compatible kidney transplants from living donors were included.
RESULTS
RESULTS
There were significantly more number of blood transfusions, previous transplants and pregnancies in HLAi transplant recipients relative to the ABOi or the control group. Mean number of therapeutic plasma exchange procedures per patient and mean plasma volume processed per procedure were slightly higher in the ABOi + HLAi category. The incidence of graft dysfunction due to suspected antibody-mediated rejection during first year was highest in the ABOi + HLAi group, followed by ABOc + HLAi and ABOi + HLAc, lowest in the ABOc + HLAc category. Mean time to first episode of graft dysfunction was significantly shorter with incompatible transplants. There were no kidney transplant recipient deaths in the study.
CONCLUSION
CONCLUSIONS
Patient outcome and graft outcomes observed with incompatible transplants were not worse than those observed with compatible transplants.
Substances chimiques
ABO Blood-Group System
0
HLA Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
299-312Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Kute VB, Agarwal SK, Sahay M, et al. Kidney-paired donation to increase living donor kidney transplantation in India: guidelines of Indian Society of Organ Transplantation-2017. Indian J Nephrol. 2018;28(1):1-9.
Tanabe K, Takahashi K, Sonda K, et al. Long-term results of ABO incompatible living kidney transplantation: a single-center experience. Transplantation. 1998;65:224-228.
Alexandre GP, Squifflet JP, de Bruyere M, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplant Proc. 1987;19:4538-4542.
Rydberg L. ABO-incompatibility in solid organ transplantation. Transfus Med. 2001;11:325-342.
Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation. 2000;70:887-895.
Sonnenday CJ, Ratner LE, Zachary AA, et al. Preemptive therapy with plasmapheresis/ intravenous immunoglobulin allows successful live donor renal transplantation in patients with a positive cross-match. Transplant Proc. 2002;34:1614-1616.
Caro-Oleas JL, Gonzalez-Escribano MF, Gonzalez-Roncero FM, et al. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transplant. 2012;27:1231-1238.
Tyden G, Donauer J, Wadstrom J, et al. Implementation of a protocol for ABO incompatible kidney transplantation-a three-center experience with 60 consecutive transplantations. Transplantation. 2007;83:1153.
Barnett AN, Manook M, Nagendran M, et al. Tailored desensitization strategies in ABO blood group antibody incompatible renal transplantation. Transpl Int. 2014;27:187-196.
Uchida J, Machida Y, Iwai T, et al. Desensitization protocol in highly HLA-sensitized and ABO-incompatible high titer kidney transplantation. Transplant Proc. 2010;42(10):3998-4002. https://doi.org/10.1016/j.transproceed.2010.09.043.
Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969;280:735-739.
Lefaucheur C, Loupy A, Hill GS, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010;21:1398-1406.
Warren DS, Zachary AA, Sonnenday CJ, et al. Successful renal transplantation across simultaneous ABO incompatible and positive crossmatch barriers. Am J Transplant. 2004;4(4):561-568.
Ko EJ, Yu JH, Yang CW, et al. Clinical outcomes of ABO-and HLA-incompatible kidney transplantation: a nationwide cohort study. Transpl Int. 2017;30(12):1215-1225.
Chung BH, Joo YY, Lee J, et al. Impact of ABO incompatibility on the development of acute antibody-mediated rejection in kidney transplant recipients presensitized to HLA. PLoS One. 2015;10(4):1-14.
Padmanabhan A, Ratner LE, Jhang JS, et al. Comparative outcome analysis of ABO-incompatible and positive crossmatch renal transplantation: a single-center experience. Transplantation. 2009;87(12):1889-1896. https://doi.org/10.1097/TP.0b013e3181a76ae1.
Transplantation of Human Organ Act, 1994. http://india.gov.in/allimpfrms/allacts/2606.pdf. Accessed on June 8, 2012.
Pandey P, Setya D, Sinha V, et al. Therapeutic apheresis in ABO-incompatible kidney and liver transplantation: a single-center experience of 50 patients. Ther Apher Dial. 2020. https://doi.org/10.1111/1744-9987.13495.
Pandey P, Setya D, Sinha V, et al. Renal transplantation in HLA sensitized patients: traversing the immunological barrier. Ther Apher Dial. 2019. https://doi.org/10.1111/1744-9987.13467.
Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604-612.
Solez K, Colvin RB, Racusen LC, et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant. 2008;8:753-760.
Couzi L, Manook M, Perera R, et al. Difference in outcomes after antibody-mediated rejection between abo-incompatible and positive cross-match transplantations. Transpl Int. 2015;28(10):1205-1215.
Massad MG, Cook DJ, Schmitt SK, et al. Factors influencing HLA sensitization in implantable LVAD recipients. Ann Thorac Surg. 1997;64(4):1120-1125. https://doi.org/10.1016/s0003-4975(97)00807-2.
Saito PK, Yamakawa RH, Aparecida EP, d Silva J'n WV, Borelli SD. Evaluation of the humoral immune response to human leukocyte antigens in Brazilian renal transplant candidates. PLoS One. 2014;9(6):e100270. https://doi.org/10.1371/journal.pone.0100270.
Lim JH, Cho JH, Jung HY, et al. Excellent outcome after desensitization in high immunologic risk kidney transplantation. PLoS One. 2019;14(9):e0222537.
Higgins R, Lowe D, Daga S, et al. Pregnancy-induced HLA antibodies respond more vigorously after renal transplantation than antibodies induced by prior transplantation. Hum Immunol. 2015;76(8):546-552.
Bromberger B, Spragan D, Hashmi S, et al. Pregnancy-induced sensitization promotes sex disparity in living donor kidney transplantation. J Am Soc Nephrol. 2017;28(10):3025-3033. https://doi.org/10.1681/ASN.2016101059.
Sahay M. Men are from mars, women are from venus: gender disparity in transplantation. Indian J. Transplant. 2019;13(4):237.
Kong JM, Ahn J, Park JB, et al. ABO incompatible living donor kidney transplantation in Korea: highly uniform protocols and good medium-term outcome. Clin Transplant. 2013;27(6):875-881. https://doi.org/10.1111/ctr.12249.
Gloor JM, DeGoey SR, Pineda AA, et al. Overcoming a positive crossmatch in living-donor kidney transplantation. Am J Transplant. 2003;3(8):1017-1023.
Yoon HE, Hyoung BJ, Hwang HS, et al. Successful renal transplantation with desensitization in highly sensitized patients: a single center experience. J Korean Med Sci. 2009;24(Suppl):S148-S155. https://doi.org/10.3346/jkms.2009.24.S1.S148.
Montgomery JR, Berger JC, Warren DS, James NT, Montgomery RA, Segev DL. Outcomes of ABO incompatible kidney transplantation in the United States. Transplantation. 2012;93(6):603-609.
Tobian AAR, Shirey RS, King KE. ABO antibody titer monitoring for incompatible renal transplantation. Transfusion. 2011;51:454-457.
Shirey RS, Cai W, Montgomery RA, Chhibber V, Ness PM, King KE. Immunohematology: Streamlining ABO antibody titrations for monitoring ABO-incompatible kidney transplants. Transfusion. 2010;50(3):631-634.
Tobian AA, Shirey RS, Montgomery RA, Ness PM, King KE. The critical role of plasmapheresis in ABO-incompatible renal transplantation. Transfusion. 2008;48(11):2453-2460.
Sullivan HC, Liwski RS, Bray RA, Gebel HM. The road to HLA antibody evaluation: do not rely on MFI. Am J Transplant. 2017;17(6):1455-1461.
Gordon EJ, Ladner DP, Caicedo JC, Franklin J. Disparities in kidney transplant outcomes: a review. Semin Nephrol. 2010;30(1):81-89. https://doi.org/10.1016/j.semnephrol.2009.10.009.
Gordon EJ, Caicedo JC. Ethnic advantages in kidney transplant outcomes: the Hispanic paradox at work? Nephrol Dial Transplant. 2008;24(4):1103-1109. https://doi.org/10.1093/ndt/gfn691.
Garcia-Garcia G, Harden P, Chapman J. The global role of kidney transplantation. Nefrologia. 2012;32(1):1-6.
Opelz G, Morath C, Süsal C, Tran TH, Zeier M, Döhler B. Three-year outcomes following 1420 ABO incompatible living-donor kidney transplants performed after ABO antibody reduction: results from 101 centers. Transplantation. 2015;99(2):400-404. https://doi.org/10.1097/TP.0000000000000312.
Lee J, Lee JG, Kim S, et al. The effect of rituximab dose on infectious complications in ABO-incompatible kidney transplantation. Nephrol Dial Transplant. 2016;31:1013-1021.
Kim MH, Jun KW, Hwang JK, et al. Risk factors for postoperative bleeding in ABO-incompatible kidney transplantation. Clin Transplant. 2015;29:365-372.
Aggarwal G, Tiwari AK, Dorwal P, et al. Successful renal transplantation across HLA barrier: report from India. Indian J Nephrol. 2017;27(3):210-214.
Jha PK, Tiwari AK, Bansal SB, Sethi SK, Ahlawat R, Kher V. Cascade plasmapheresis as preconditioning regimen for ABO-incompatible renal transplantation: a single-center experience. Transfusion. 2016;56(4):956-961.
Ray DS, Thukral S. Outcome of ABO-incompatible living donor renal transplantations: a single-center experience from eastern India. Transplant Proc. 2016;48(8):2622-2628.
Jha PK, Nandwani A, Kher A, et al. ABO-incompatible renal transplantation: the journey so far on a road less traveled. Indian J Nephrol. 2018;12(3):177.
Jha PK, Bansal SB, Sethi SK, et al. ABO-incompatible renal transplantation in developing world-crossing the immunological (and mental) barrier. Indian J Nephrol. 2016;26(2):113-118.
Bansal S, Gade A. P1791 HLA desensitization-indian experience. Nephrol Dial Transplant. 2020;35(suppl 3):gfaa142-P1791.
Mittal T, Ramachandran R, Kumar V, et al. Outcomes of spousal versus related donor kidney transplants: a comparative study. Indian J Nephrol. 2014;24(1):3.
Sinha A, Hari P, Guleria S, et al. Outcome of pediatric renal transplantation in North India. Pediatr Transplant. 2010 Nov;14(7):836-843.